OncoCyte Corp (OncoCyte) is a molecular diagnostic company that develops solutions for the detection and treatment of cancer. The company offers a predictive molecular test to identify patients with early-stage non-squamous non-small cell lung cancer. It develops DetermaIO, a gene expression test to identify immunotherapy drug responders; and DetermaCNI, a test used to measure and monitor cancer treatment. Oncocyte offers biopharma services such as target discovery; assay design, development and validation; and clinical trial and testing services. The company operates in Germany and the US. OncoCyte is headquartered in Irvine, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company OncoCyte Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- OncoCyte Corp Company Overview
- OncoCyte Corp Company Snapshot
- OncoCyte Corp Pipeline Products and Ongoing Clinical Trials Overview
- OncoCyte Corp - Pipeline Analysis Overview
- OncoCyte Corp - Key Facts
- OncoCyte Corp - Major Products and Services
- OncoCyte Corp Pipeline Products by Development Stage
- OncoCyte Corp Ongoing Clinical Trials by Trial Status
- OncoCyte Corp Pipeline Products Overview
- ALK Resistance Monitoring Assay
- ALK Resistance Monitoring Assay Product Overview
- Breast Confirmatory BI RADS 3-4 Assay
- Breast Confirmatory BI RADS 3-4 Assay Product Overview
- Companion Diagnostic Test - Alzheimer’s Disease
- Companion Diagnostic Test - Alzheimer’s Disease Product Overview
- Companion Diagnostic Test - Amyotrophic Lateral Sclerosis
- Companion Diagnostic Test - Amyotrophic Lateral Sclerosis Product Overview
- Companion Diagnostic Test - Breast Cancer
- Companion Diagnostic Test - Breast Cancer Product Overview
- Companion Diagnostic Test - Chronic Fatigue Syndrome
- Companion Diagnostic Test - Chronic Fatigue Syndrome Product Overview
- Companion Diagnostic Test - Colorectal Cancer
- Companion Diagnostic Test - Colorectal Cancer Product Overview
- Companion Diagnostic Test - Multiple Sclerosis
- Companion Diagnostic Test - Multiple Sclerosis Product Overview
- Companion Diagnostic Test - Parkinson’s Disease
- Companion Diagnostic Test - Parkinson’s Disease Product Overview
- Companion Diagnostic Test - Prostate Cancer
- Companion Diagnostic Test - Prostate Cancer Product Overview
- Companion Diagnostic Test - Rheumatoid Arthritis
- Companion Diagnostic Test - Rheumatoid Arthritis Product Overview
- Dense Breast Tissue Confirmatory Test - Breast Cancer
- Dense Breast Tissue Confirmatory Test - Breast Cancer Product Overview
- DetermaCNI
- DetermaCNI Product Overview
- DetermaDx
- DetermaDx Product Overview
- DetermaIO
- DetermaIO Product Overview
- DetermaIO Clinical Trial
- DetermaMX
- DetermaMX Product Overview
- DetermaTx
- DetermaTx Product Overview
- Diagnostic Assay - Amyloidosis
- Diagnostic Assay - Amyloidosis Product Overview
- Diagnostic Assay - Autism Spectrum Disorder
- Diagnostic Assay - Autism Spectrum Disorder Product Overview
- Diagnostic Assay - HPV
- Diagnostic Assay - HPV Product Overview
- Diagnostic Assay - Type I Diabetes
- Diagnostic Assay - Type I Diabetes Product Overview
- Diagnostic Test - Brain Cancer
- Diagnostic Test - Brain Cancer Product Overview
- Diagnostic Test - Gulf War Illnesses
- Diagnostic Test - Gulf War Illnesses Product Overview
- Diagnostic Test - Huntington's Disease
- Diagnostic Test - Huntington's Disease Product Overview
- Diagnostic Test - Lung Cancer
- Diagnostic Test - Lung Cancer Product Overview
- Diagnostic Test - Ovarian Cancer
- Diagnostic Test - Ovarian Cancer Product Overview
- Diagnostic Test - Systemic Lupus Erythematous
- Diagnostic Test - Systemic Lupus Erythematous Product Overview
- Insight ALK ECD Assay
- Insight ALK ECD Assay Product Overview
- Insight DEPDC1 Screen Assay
- Insight DEPDC1 Screen Assay Product Overview
- Insight ROS1 Fusion Screen Assay
- Insight ROS1 Fusion Screen Assay Product Overview
- KIR/KIR-Ligand LDT Assay
- KIR/KIR-Ligand LDT Assay Product Overview
- Lung Screening Assay
- Lung Screening Assay Product Overview
- Next-Generation DetermaVu
- Next-Generation DetermaVu Product Overview
- NGS Lung Panel Test
- NGS Lung Panel Test Product Overview
- PanC-Dx - Bladder Cancer
- PanC-Dx - Bladder Cancer Product Overview
- PanC-Dx - Breast Cancer
- PanC-Dx - Breast Cancer Product Overview
- PanC-Dx - Breast Cancer Clinical Trial
- PanC-Dx - Colon Cancer
- PanC-Dx - Colon Cancer Product Overview
- PanC-Dx - Lung Cancer
- PanC-Dx - Lung Cancer Product Overview
- PanC-Dx - Prostate Cancer
- PanC-Dx - Prostate Cancer Product Overview
- Therapeutic Monitoring Test - Pancreatic Cancer
- Therapeutic Monitoring Test - Pancreatic Cancer Product Overview
- Therasure Transplant Monitor Test - LDT
- Therasure Transplant Monitor Test - LDT Product Overview
- Tumor Type 4 Assay
- Tumor Type 4 Assay Product Overview
- OncoCyte Corp - Key Competitors
- OncoCyte Corp - Key Employees
- OncoCyte Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- OncoCyte Corp, Recent Developments
- Mar 31, 2023: Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
- Mar 29, 2023: Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
- Mar 02, 2023: Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
- Nov 30, 2022: Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
- Nov 30, 2022: Oncocyte Announces Executive Leadership Changes
- Nov 10, 2022: Oncocyte Reports Third Quarter 2022 Financial Results
- Aug 31, 2022: Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
- Mar 28, 2022: Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
- Mar 10, 2022: Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Nov 09, 2021: Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- OncoCyte Corp Pipeline Products and Ongoing Clinical Trials Overview
- OncoCyte Corp Pipeline Products by Equipment Type
- OncoCyte Corp Pipeline Products by Indication
- OncoCyte Corp Ongoing Clinical Trials by Trial Status
- OncoCyte Corp, Key Facts
- OncoCyte Corp, Major Products and Services
- OncoCyte Corp Number of Pipeline Products by Development Stage
- OncoCyte Corp Pipeline Products Summary by Development Stage
- OncoCyte Corp Ongoing Clinical Trials by Trial Status
- OncoCyte Corp Ongoing Clinical Trials Summary
- ALK Resistance Monitoring Assay - Product Status
- ALK Resistance Monitoring Assay - Product Description
- Breast Confirmatory BI RADS 3-4 Assay - Product Status
- Breast Confirmatory BI RADS 3-4 Assay - Product Description
- Companion Diagnostic Test - Alzheimer’s Disease - Product Status
- Companion Diagnostic Test - Alzheimer’s Disease - Product Description
- Companion Diagnostic Test - Amyotrophic Lateral Sclerosis - Product Status
- Companion Diagnostic Test - Amyotrophic Lateral Sclerosis - Product Description
- Companion Diagnostic Test - Breast Cancer - Product Status
- Companion Diagnostic Test - Breast Cancer - Product Description
- Companion Diagnostic Test - Chronic Fatigue Syndrome - Product Status
- Companion Diagnostic Test - Chronic Fatigue Syndrome - Product Description
- Companion Diagnostic Test - Colorectal Cancer - Product Status
- Companion Diagnostic Test - Colorectal Cancer - Product Description
- Companion Diagnostic Test - Multiple Sclerosis - Product Status
- Companion Diagnostic Test - Multiple Sclerosis - Product Description
- Companion Diagnostic Test - Parkinson’s Disease - Product Status
- Companion Diagnostic Test - Parkinson’s Disease - Product Description
- Companion Diagnostic Test - Prostate Cancer - Product Status
- Companion Diagnostic Test - Prostate Cancer - Product Description
- Companion Diagnostic Test - Rheumatoid Arthritis - Product Status
- Companion Diagnostic Test - Rheumatoid Arthritis - Product Description
- Dense Breast Tissue Confirmatory Test - Breast Cancer - Product Status
- Dense Breast Tissue Confirmatory Test - Breast Cancer - Product Description
- DetermaCNI - Product Status
- DetermaCNI - Product Description
- DetermaDx - Product Status
- DetermaDx - Product Description
- DetermaIO - Product Status
- DetermaIO - Product Description
- DetermaIO - A Randomized, Phase Iii Trial to Evaluate the Efficacy and Safety of Pembrolizumab (Mk-3475) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer with ≫/= 1 Cm Residual Invasive Cancer or Positive Lymph Nodes (Ypn1mi, Ypn1-3) after Neoadjuvant Chemotherapy
- DetermaIO - Neo-adjuvant Study with the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment with Nab-paclitaxel and Carboplatin
- DetermaMX - Product Status
- DetermaMX - Product Description
- DetermaTx - Product Status
- DetermaTx - Product Description
- Diagnostic Assay - Amyloidosis - Product Status
- Diagnostic Assay - Amyloidosis - Product Description
- Diagnostic Assay - Autism Spectrum Disorder - Product Status
- Diagnostic Assay - Autism Spectrum Disorder - Product Description
- Diagnostic Assay - HPV - Product Status
- Diagnostic Assay - HPV - Product Description
- Diagnostic Assay - Type I Diabetes - Product Status
- Diagnostic Assay - Type I Diabetes - Product Description
- Diagnostic Test - Brain Cancer - Product Status
- Diagnostic Test - Brain Cancer - Product Description
- Diagnostic Test - Gulf War Illnesses - Product Status
- Diagnostic Test - Gulf War Illnesses - Product Description
- Diagnostic Test - Huntington's Disease - Product Status
- Diagnostic Test - Huntington's Disease - Product Description
- Diagnostic Test - Lung Cancer - Product Status
- Diagnostic Test - Lung Cancer - Product Description
- Diagnostic Test - Ovarian Cancer - Product Status
- Diagnostic Test - Ovarian Cancer - Product Description
- Diagnostic Test - Systemic Lupus Erythematous - Product Status
- Diagnostic Test - Systemic Lupus Erythematous - Product Description
- Insight ALK ECD Assay - Product Status
- Insight ALK ECD Assay - Product Description
- Insight DEPDC1 Screen Assay - Product Status
- Insight DEPDC1 Screen Assay - Product Description
- Insight ROS1 Fusion Screen Assay - Product Status
- Insight ROS1 Fusion Screen Assay - Product Description
- KIR/KIR-Ligand LDT Assay - Product Status
- KIR/KIR-Ligand LDT Assay - Product Description
- Lung Screening Assay - Product Status
- Lung Screening Assay - Product Description
- Next-Generation DetermaVu - Product Status
- Next-Generation DetermaVu - Product Description
- NGS Lung Panel Test - Product Status
- NGS Lung Panel Test - Product Description
- PanC-Dx - Bladder Cancer - Product Status
- PanC-Dx - Bladder Cancer - Product Description
- PanC-Dx - Breast Cancer - Product Status
- PanC-Dx - Breast Cancer - Product Description
- PanC-Dx - Breast Cancer - Clinical Study of PanC-Dx for Breast Cancer and Other Types of Human Cancers
- PanC-Dx - Colon Cancer - Product Status
- PanC-Dx - Colon Cancer - Product Description
- PanC-Dx - Lung Cancer - Product Status
- PanC-Dx - Lung Cancer - Product Description
- PanC-Dx - Prostate Cancer - Product Status
- PanC-Dx - Prostate Cancer - Product Description
- Therapeutic Monitoring Test - Pancreatic Cancer - Product Status
- Therapeutic Monitoring Test - Pancreatic Cancer - Product Description
- Therasure Transplant Monitor Test - LDT - Product Status
- Therasure Transplant Monitor Test - LDT - Product Description
- Tumor Type 4 Assay - Product Status
- Tumor Type 4 Assay - Product Description
- OncoCyte Corp, Key Employees
- OncoCyte Corp, Other Locations
- OncoCyte Corp, Subsidiaries
- Glossary
- OncoCyte Corp Pipeline Products by Equipment Type
- OncoCyte Corp Pipeline Products by Development Stage
- OncoCyte Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Net Medical Xpress Solutions Inc
- Biodesix Inc
- Celcuity Inc
- Lineage Cell Therapeutics Inc
- Co-Diagnostics Inc
